Stryker Corporation’s Spine and Trauma & Extremities divisions will be launching the BIO4 viable bone matrix at booth #443 during the American Academy of Orthopaedic Surgeons Annual Meeting (24–28 March, Las Vegas, USA).
Osiris Therapeutics, the creators of the original allograft cellular bone matrix, have introduced BIO4, a viable bone matrix containing endogenous bone forming cells including mesenchymal stem cells, osteoprogenitor cells, osteoblasts, osteoinductive and angiogenic growth factors. BIO4 possesses all four characteristics involved in bone repair and regeneration: osteoconductive, osteoinductive, osteogenic and angiogenic. The company says that it is a safe alternative to bone autograft that minimises the potential for harvest site co-morbidities.
“With the introduction of BIO4, Stryker now plays in the growing US$199m cellular allograft market,” said Spencer Stiles, president, Stryker Spine. “Stryker offers one of the most comprehensive biologics portfolios on the market featuring the number one selling synthetic bone graft, Vitoss, and the next generation viable bone matrix, BIO4.”
